Activity of FCE 22101 against methicillin-resistant Staphylococcus aureus and affinity for penicillin binding proteins.
The susceptibility of 47 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to FCE 22101, imipenem and methicillin was determined with Iso-Sensitest media, with or without NaCl and with incubation at 30 degrees and 37 degrees C and for 24 and 48 h. All strains had a MIC 8 mg/l of methicillin under at least one of the culture conditions. The MIC90 of FCE 22101 was 1 mg/l, and that of imipenem 16 mg/l. The affinity of FCE 22101 for the penicillin-binding proteins (PBPs) of five clinical isolates of MRSA and S. aureus 13136 p-m+ was examined in envelope preparations and whole cell assay under the growth conditions listed above. PBP 2' was detected in all MRSA, and the clinical isolates had an I50 of 4 mg/l FCE 22101. These in-vitro data suggest that FCE 22101 may be active against MRSA in clinical use.
Piddock
L J
LJ
Department of Medical Microbiology, Medical School, University of Birmingham, UK.
Traynor
E A
EA
Wise
R
R
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001426:Bacterial Proteins; D015780:Carbapenems; D002352:Carrier Proteins / Q000378:metabolism*; D006602:Hexosyltransferases; D015378:Imipenem / Q000494:pharmacology; D008712:Methicillin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D002267:Muramoylpentapeptide Carboxypeptidase / Q000378:metabolism*; D010403:Penicillin Resistance; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases; D013211:Staphylococcus aureus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D002352:Carrier Proteins; D046915:Penicillin-Binding Proteins; D015378:Imipenem; C040033:ritipenem; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase; D008712:Methicillin